| Nov 7 |
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
|
| Nov 5 |
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
| Oct 15 |
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 10 |
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
|
| Sep 4 |
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Jul 23 |
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Jun 7 |
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
|
| Jun 6 |
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
|
| Jun 4 |
Recent Run-Up Provides MAIA Biotechnology With Breathing Room
|
| Jun 4 |
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
|
